Literature DB >> 23081979

Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients.

Ana M Suelves1, Tong Z Zhao, Sana S Siddique, C Stephen Foster.   

Abstract

PURPOSE: We investigated the expression of IL-1, IL-6, IL-12, IL-13, and IL-17 in the conjunctiva of patients with ocular cicatricial pemphigoid (OCP), also labeled as ocular mucous membrane pemphigoid (MMP).
METHODS: A retrospective case-control study was done on 5 biopsy-proven OCP subjects and 6 healthy volunteers. Conjunctival specimens were obtained, and the local expression of IL-1, IL-6, IL-12, IL-13, and IL-17 was studied by immunohistochemistry. Clinical and therapeutic features were collected during follow-up.
RESULTS: No remarkable IL-1, IL-6, IL-12, IL-13, or IL-17 expression was observed in normal conjunctival specimens. All OCP samples had remarkable amounts of IL-12 and IL-17 expression especially in the epithelium and stroma; there also was stromal overexpression of IL-6. The mean follow-up after the biopsy was 13 months (range 9-15 months).
CONCLUSIONS: Our results demonstrated, for the first time to our knowledge, a local overexpression of IL-6, IL-12, and IL-17 in conjunctiva of OCP compared to controls.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23081979     DOI: 10.1167/iovs.11-9322

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

2.  A gene network bioinformatics analysis for pemphigoid autoimmune blistering diseases.

Authors:  Antonio Barone; Paolo Toti; Maria Rita Giuca; Giacomo Derchi; Ugo Covani
Journal:  Clin Oral Investig       Date:  2014-11-08       Impact factor: 3.573

3.  Tofacitinib for refractory ocular mucous membrane pemphigoid.

Authors:  Hayley James; Grace L Paley; Richard Brasington; Philip L Custer; Todd P Margolis; Michael A Paley
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-21

4.  Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Authors:  Coralie Zumelzu; Marina Alexandre; Christelle Le Roux; Patricia Weber; Alexis Guyot; Annie Levy; Françoise Aucouturier; Sabine Mignot-Grootenboer; Frédéric Caux; Eve Maubec; Catherine Prost-Squarcioni
Journal:  Front Med (Lausanne)       Date:  2018-09-27

Review 5.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

6.  Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate.

Authors:  Kevin M Burningham; Jennifer Cao; Arturo R Dominguez
Journal:  JAAD Case Rep       Date:  2022-07-16

7.  IL-17 expression in dermatitis herpetiformis and bullous pemphigoid.

Authors:  Agnieszka Zebrowska; Malgorzata Wagrowska-Danilewicz; Marian Danilewicz; Olga Stasikowska-Kanicka; Anna Cynkier; Anna Sysa-Jedrzejowska; Elzbieta Waszczykowska
Journal:  Mediators Inflamm       Date:  2013-07-21       Impact factor: 4.711

8.  Benzalkonium chloride-induced myofibroblastic transdifferentiation of Tenon's capsule fibroblasts is inhibited by coculture with corneal epithelial cells or by interleukin-10.

Authors:  Chiemi Yamashiro; Kazuhiro Tokuda; Yuka Kobayashi; Fumiaki Higashijima; Takuya Yoshimoto; Manami Ota; Tadahiko Ogata; Atsushige Ashimori; Masaaki Kobayashi; Makoto Hatano; Sho-Hei Uchi; Makiko Wakuta; Shinichiro Teranishi; Kazuhiro Kimura
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.